PCM
ZYME icon

Prelude Capital Management’s Zymeworks ZYME Stock Holding History

Prelude Capital Management’s Portfolio ZYME Stock Details ZYME Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2020
Q1 		– Sell
-12,900
Closed -$586K – 2123
2019
Q4 		$586K Sell
12,900
-10,700
-45% -$389K 0.02% 523
2019
Q3 		$585K Buy
+23,600
New +$591K 0.03% 481

Other funds holding ZYME

AC
Armistice Capital New York $5.62B AUM 36.06% 1-Year Est. Return
RG
Redmile Group San Francisco, California $1.51B AUM 164.17% 1-Year Est. Return
EAM
Eventide Asset Management Boston, Massachusetts $6.05B AUM 76.64% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
PA
Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return
CCM
Camber Capital Management Boston, Massachusetts $1.07B AUM 8.19% 1-Year Est. Return
CS
Credit Suisse Zurich, Switzerland $104B AUM 34.76% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
WP
Woodline Partners San Francisco, California $26.4B AUM 44.85% 1-Year Est. Return
BNP Paribas Asset Management
BNP Paribas Asset Management Paris, France $86.1B AUM 29.11% 1-Year Est. Return

Prelude Capital Management's ZYME Position: Q3 2022 in Review

Prelude Capital Management sold out of Zymeworks (ZYME) in Q3 2022, closing a stake of 18,570 shares — an estimated $98K sold.

Prelude Capital Management first reported a position in ZYME in Q3 2019 and held it in 7 quarters. The position peaked at $1.36M in Q4 2019. 91 funds tracked by Wall St. Rank hold ZYME as of Q3 2022.

  • Prelude Capital Management reported no remaining Zymeworks position as of Q3 2022 after selling out during the quarter.
  • Prelude Capital Management sold 18,570 Zymeworks shares in Q3 2022, an estimated $98K.
  • Prelude Capital Management first reported a position in Zymeworks in Q3 2019 and held it in 7 quarters.
  • Prelude Capital Management's Zymeworks position peaked at $1.36M in Q4 2019.
  • 91 funds tracked by Wall St. Rank held Zymeworks as of Q3 2022.

Based on Prelude Capital Management's 13F filing for Q3 2022, filed 14 Nov 2022.